|
||||||||||||||||||||||||||
| SEC Info℠ | | | Home | | | Search | | | My Interests | | | Help | | | Sign In | | | Please Sign In | |||||||
|
||||||||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 11/13/23 Y-mAbs Therapeutics, Inc. 10-Q 9/30/23 82:8.1M Toppan Merrill Bridge/FA |
Document/Exhibit Description Pages Size
1: 10-Q Quarterly Report HTML 1.37M
2: EX-10.1 Material Contract HTML 33K
3: EX-31.1 Certification -- §302 - SOA'02 HTML 29K
4: EX-31.2 Certification -- §302 - SOA'02 HTML 29K
5: EX-32.1 Certification -- §906 - SOA'02 HTML 25K
6: EX-32.2 Certification -- §906 - SOA'02 HTML 25K
12: R1 Document and Entity Information HTML 77K
13: R2 Consolidated Balance Sheets HTML 119K
14: R3 Consolidated Balance Sheets (Parenthetical) HTML 36K
15: R4 Consolidated Statements of Net Loss and HTML 101K
Comprehensive Loss
16: R5 Consolidated Statements of Changes in HTML 92K
Stockholders' Equity
17: R6 Consolidated Statements of Cash Flows HTML 87K
18: R7 Organization and Description of Business HTML 26K
19: R8 Basis of Presentation HTML 31K
20: R9 Summary of Significant Accounting Policies HTML 88K
21: R10 Product Revenue, Net HTML 60K
22: R11 Net Loss Per Share HTML 51K
23: R12 Inventories HTML 57K
24: R13 Intangible Assets, Net HTML 26K
25: R14 Accrued Liabilities HTML 43K
26: R15 License Agreements and Commitments HTML 157K
27: R16 Stockholders' Equity HTML 34K
28: R17 Share-Based Compensation HTML 98K
29: R18 Income Taxes HTML 30K
30: R19 Other Benefits HTML 25K
31: R20 Restructuring Charge HTML 27K
32: R21 Summary of Significant Accounting Policies HTML 113K
(Policies)
33: R22 Summary of Significant Accounting Policies HTML 61K
(Tables)
34: R23 Product Revenue, Net (Tables) HTML 51K
35: R24 Net Loss Per Share (Tables) HTML 49K
36: R25 Inventories (Tables) HTML 55K
37: R26 Accrued Liabilities (Tables) HTML 43K
38: R27 License Agreements and Commitments (Tables) HTML 137K
39: R28 Share-Based Compensation (Tables) HTML 86K
40: R29 BASIS OF PRESENTATION - Accumulated deficit HTML 26K
(Details)
41: R30 BASIS OF PRESENTATION - Cash and cash equivalents HTML 26K
(Details)
42: R31 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - HTML 31K
Concentration of Credit Risk (Details)
43: R32 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - HTML 25K
Inventories (Details)
44: R33 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Fair HTML 41K
Value Measurements (Details)
45: R34 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - HTML 24K
Operating Leases (Details)
46: R35 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - HTML 33K
Revenue Recognition - Product revenue, net
(Details)
47: R36 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - HTML 58K
Revenue Recognition - License revenue (Details)
48: R37 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - HTML 25K
Segment Information (Details)
49: R38 PRODUCT REVENUE, NET - Product revenue and HTML 52K
receivables (Details)
50: R39 PRODUCT REVENUE, NET - Reserves for discounts and HTML 66K
allowances (Details)
51: R40 PRODUCT REVENUE, NET - Concentrations (Details) HTML 55K
52: R41 NET LOSS PER SHARE - Basic and diluted (Details) HTML 50K
53: R42 NET LOSS PER SHARE - Anti-dilutive securities HTML 25K
(Details)
54: R43 Inventories (Details) HTML 44K
55: R44 Intangible Assets, Net (Details) HTML 44K
56: R45 Accrued Liabilities (Details) HTML 36K
57: R46 LICENSE AGREEMENTS AND COMMITMENTS - MSK License HTML 29K
Agreement (Details)
58: R47 LICENSE AGREEMENTS AND COMMITMENTS - SADA License HTML 36K
Agreement (Details)
59: R48 LICENSE AGREEMENTS AND COMMITMENTS - Summary of HTML 63K
Significant Agreements and Commitments (Details)
60: R49 LICENSE AGREEMENTS AND COMMITMENTS - Lease HTML 44K
agreements (Details)
61: R50 LICENSE AGREEMENTS AND COMMITMENTS - Lease costs HTML 33K
(Details)
62: R51 LICENSE AGREEMENTS AND COMMITMENTS - Lease HTML 40K
maturities (Details)
63: R52 LICENSE AGREEMENTS AND COMMITMENTS - Lease term HTML 27K
and discount rate (Details)
64: R53 LICENSE AGREEMENTS AND COMMITMENTS - Severance HTML 32K
Related Benefits (Details)
65: R54 LICENSE AGREEMENTS AND COMMITMENTS - Legal matters HTML 28K
(Details)
66: R55 STOCKHOLDERS' EQUITY - Authorized, Common and HTML 42K
Preferred Stock (Details)
67: R56 STOCKHOLDERS' EQUITY - Stock Grant Agreements with HTML 59K
Non Employees (Details)
68: R57 SHARE-BASED COMPENSATION - 2015 Plan (Details) HTML 36K
69: R58 SHARE-BASED COMPENSATION - 2018 Plan (Details) HTML 55K
70: R59 SHARE-BASED COMPENSATION - Stock-based HTML 45K
compensation expense - Options (Details)
71: R60 SHARE-BASED COMPENSATION - Stock option activity HTML 62K
(Details)
72: R61 SHARE-BASED COMPENSATION - Stock option grants HTML 60K
(Details)
73: R62 SHARE-BASED COMPENSATION - Stock option HTML 36K
unrecognized compensation (Details)
74: R63 SHARE-BASED COMPENSATION - Restricted Stock Unit HTML 74K
Activity (Details)
75: R64 INCOME TAXES - Loss before income taxes (Details) HTML 36K
76: R65 Other Benefits (Details) HTML 31K
77: R66 Restructuring Charge (Details) HTML 40K
80: XML IDEA XML File -- Filing Summary XML 145K
78: XML XBRL Instance -- ymab-20230930x10q_htm XML 1.77M
79: EXCEL IDEA Workbook of Financial Report Info XLSX 105K
8: EX-101.CAL XBRL Calculations -- ymab-20230930_cal XML 127K
9: EX-101.DEF XBRL Definitions -- ymab-20230930_def XML 617K
10: EX-101.LAB XBRL Labels -- ymab-20230930_lab XML 1.18M
11: EX-101.PRE XBRL Presentations -- ymab-20230930_pre XML 944K
7: EX-101.SCH XBRL Schema -- ymab-20230930 XSD 184K
81: JSON XBRL Instance as JSON Data -- MetaLinks 407± 587K
82: ZIP XBRL Zipped Folder -- 0001558370-23-018827-xbrl Zip 333K
 | Download this zipped .zip folder |
| Files: | ymab-20230930.xsd ymab-20230930_cal.xml ymab-20230930_def.xml ymab-20230930_lab.xml ymab-20230930_pre.xml ymab-20230930x10q.htm ymab-20230930xex10d1.htm ymab-20230930xex31d1.htm ymab-20230930xex31d2.htm ymab-20230930xex32d1.htm ymab-20230930xex32d2.htm |
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 2/29/24 Y-mAbs Therapeutics, Inc. 10-K 12/31/23 101:10M Toppan Merrill Bridge/FA |
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 10/18/23 Y-mAbs Therapeutics, Inc. 8-K:5,7,9 10/12/23 13:454K Toppan Merrill/FA 9/26/18 Y-mAbs Therapeutics, Inc. 8-K:5,7,9 9/25/18 4:284K Toppan Merrill/FA |